Breaking News

GBI Secures Commercial Manufacturing Contract

Master supply agreement is for commercializing a radioimmunoconjugate product.

GBI BioManufacturing, a contract development and manufacturing organization (CDMO), signed its second master supply agreement (MSA) for commercializing a radioimmunoconjugate product.

“We are thrilled to announce the signing of our second commercial contract, a testament to the exceptional capabilities and unwavering commitment of the entire GBI team,” said Darrin Schellin, CEO. “This achievement highlights our expertise and experience in the radiopharmaceutical sector, and it also highlights the confidence that our clients place in us.”

“We are happy to see more clients entrusting us with their long-term commercial product needs,” said Karl Pinto, chairman of the board at GBI. “This announcement signifies the strength, longevity and strategic nature of our partnership with this fast growing, global radiopharmaceutical leader.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters